Redmile Group, LLC's Form 4 filing
ADC Therapeutics SAADCT · filed Apr 2, 2026
- Accession no.
- 0001104659-26-039359
- Filed
- Apr 2, 2026, 9:00 PM ET
- Trade date
- Mar 31-Apr 2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions. Open-market sales total $19.6M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Redmile Group, LLCCIK 0001425738 | 10% Owner |
| Green JeremyCIK 0001650527 | 10% Owner |
| RedCo II Master Fund, L.P.CIK 0001921783 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | Common Stock | SSaleDisposed | −196,229 | $3.75F3 | −$736,251.21 | 15,470,502 | Indirect | |
| Mar 31, 2026 | Common Stock | SSaleDisposed | −188,407 | $3.75F3 | −$706,903.06 | 12,957,305 | Direct | |
| Apr 1, 2026 | Common Stock | SSaleDisposed | −169,265 | $3.80F4 | −$643,037.74 | 15,301,237 | Indirect | |
| Apr 1, 2026 | Common Stock | SSaleDisposed | −162,517 | $3.80F4 | −$617,402.08 | 12,794,788 | Direct | |
| Apr 2, 2026 | Common Stock | SSaleDisposed | −2,634,506 | $3.28F5 | −$8,638,545.17 | 12,666,731 | Indirect | |
| Apr 2, 2026 | Common Stock | SSaleDisposed | −2,529,491 | $3.28F5 | −$8,294,200.99 | 10,265,297 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.63 to $3.81, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
Referenced by the price of 2 transactions in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.83, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
Referenced by the price of 2 transactions in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.77, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
Referenced by the price of 2 transactions in Table I.
Remarks
The sales reported herein were effected within a period of less than six months from the purchases of pre-funded warrants to purchase the Issuers' Common Stock reported in the Form 4 filed by the Reporting Persons on October 28, 2025. However, the sales reported herein were effected at a price lower than the previous purchases that were reported in the Form 4 filed on October 28, 2025, such that no profits have been earned by the Reporting Persons, and so the Reporting Persons have no additional liability under Section 16(b).